EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genomic and Phenotypic Safety Assessment of Probiotic Bacillus coagulans Strain JBI-YZ6.3

Yongmei Zhang, Tom J Overbeck, Victoria L Palmer Skebba, Neil N Gandhi

Probiotics and Antimicrobial Proteins · 2025-10 · 17 (5) · 3440-3450

DOI: 10.1007/s12602-024-10305-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Probiotics and Antimicrobial Proteins, online erschienen am 19.06.2024. Verfasst von Yongmei Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Jeneil Biotech, Inc, Saukville, WI, 53080, USA. y.zhang@jeneilbiotech.com. Hauptthemen laut MEDLINE: Probiotics, Bacillus coagulans. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jeneil Biotech, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Spore-forming Bacillus coagulans has been widely recognized as an important probiotic, which is commonly used in products for human consumption and animal feeds. B . coagulans exhibits beneficial traits from both Bacillus and lactic acid-producing Lactobacillus . The present study evaluated the safety of the newly isolated B. coagulans strain JBI-YZ6.3, using combined genomic and phenotypic analysis approaches. The taxonomic classification based on genome sequence and biochemical tests identified strain JBI-YZ6.3 as B. coagulans . Comprehensive genome-based analyses established JBI-YZ6.3 as a novel strain of B. coagulans . Antibiotic susceptibility testing showed that the strain JBI-YZ6.3 was sensitive to a panel of fourteen antibiotics, and no genes related to antibiotic resistance were found in its genome. The spores of strain JBI-YZ6.3 exhibited tolerance to acid and bile salts, as well as stability at ambient and elevated conditions of temperature and relative humidity. There were no homologs of Bacillus toxin genes identified in the genome of JBI-YZ6.3, and the strain exhibited no cytotoxicity towards Vero cells and human peripheral blood mononuclear cells. In conclusion, findings from this study support the safety of B. coagulans strain JBI-YZ6.3, which can be developed into new probiotic products for preventive and therapeutic benefits in human and animal hosts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsBacillus coagulansHumansAnimalsGenome, BacterialVero CellsChlorocebus aethiopsPhenotypeAnti-Bacterial AgentsMicrobial Sensitivity TestsGenomicsLeukocytes, MononuclearSpores, Bacterial

Stichwörter der Autor:innen

Bacillus coagulansAntibiotic resistanceGenomic analysisPhylogenyProbioticsSafety assessment

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Jeneil Biotech, Inc, Saukville, WI, 53080, USA. y.zhang@jeneilbiotech.com.
  • Jeneil Biotech, Inc, Saukville, WI, 53080, USA.

Förderung

  • Jeneil Biotech, Inc.

Zitieren

APA

Zhang, Y., Overbeck, T. J., Skebba, V. L. P., & Gandhi, N. N. (2025). Genomic and Phenotypic Safety Assessment of Probiotic Bacillus coagulans Strain JBI-YZ6.3. Probiotics and Antimicrobial Proteins, 17(5), 3440-3450. https://doi.org/10.1007/s12602-024-10305-4

Vancouver

Zhang Y, Overbeck TJ, Skebba VLP, Gandhi NN. Genomic and Phenotypic Safety Assessment of Probiotic Bacillus coagulans Strain JBI-YZ6.3. Probiotics and Antimicrobial Proteins. 2025;17(5):3440-3450. doi:10.1007/s12602-024-10305-4

BibTeX
@article{Zhang2025,
  author = {Zhang, Yongmei and Overbeck, Tom J and Skebba, Victoria L Palmer and Gandhi, Neil N},
  title = {Genomic and Phenotypic Safety Assessment of Probiotic Bacillus coagulans Strain JBI-YZ6.3},
  journal = {Probiotics and Antimicrobial Proteins},
  year = {2025},
  volume = {17},
  number = {5},
  pages = {3440--3450},
  doi = {10.1007/s12602-024-10305-4}
}
Kostenlos starten →